Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
Anti-cancer immunotherapies, particularly immune checkpoint inhibitors, have significantly advanced oncology treatments but are associated with rare, potentially severe cardiotoxicities. Despite their success, these therapies are associated with immune-related adverse events including rare but sever...
Saved in:
| Main Authors: | Wu Helena T., Hsu Vanessa, Win Shwe, Xing Yan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
EDP Sciences
2025-01-01
|
| Series: | Visualized Cancer Medicine |
| Subjects: | |
| Online Access: | https://vcm.edpsciences.org/articles/vcm/full_html/2025/01/vcm20240019/vcm20240019.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiotoxicity in cancer immunotherapy: a systematic review and global meta-analysis
by: Fanlin Zhou, et al.
Published: (2025-07-01) -
The role of immunotherapy in the treatment of skin melanoma: a contemporary perspective
by: P. S. Masaeva
Published: (2024-06-01) -
Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
by: Tuba N. Gide, et al.
Published: (2023-12-01) -
The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives
by: Sana Ahuja, et al.
Published: (2024-12-01) -
Research hotspots and trends of immunotherapy and melanoma: A bibliometric analysis during 2014–2024
by: Zixuan Jia, et al.
Published: (2025-12-01)